Divi's Lab: Reports Q1 Revenue of 30.8 Billion Rupees, Up From 24 Billion Last Year.

 01 Aug 2026 01:13 PM

Divi's Lab: Reports Q1 Revenue of 30.8 Billion Rupees, Up From 24 Billion Last Year.

Divi's Lab: Reports 28.33% Revenue Growth Year Over Year in Q1.

 01 Aug 2026 01:13 PM

Divi's Lab: Reports 28.33% Revenue Growth Year Over Year in Q1.

Divi's Lab: Reports Q1 EBITDA of 12.55 Billion Rupees Compared to 7.3 Billion Last Year; Q1 EBITDA Margin Increases to 40.75% From 30.25% Year Over Year.

 01 Aug 2026 01:13 PM

Divi's Lab: Reports Q1 EBITDA of 12.55 Billion Rupees Compared to 7.3 Billion Last Year; Q1 EBITDA Margin Increases to 40.75% From 30.25% Year Over Year.

Divi's Lab: Citi on Divi's Laboratories Maintains Buy with Target Price of ₹9,450 as GLP-1 and complex oral peptide opportunities (Tirzepatide, Orforglipron, Enlicitide, Icotrokinra) provide strong CY27–30 growth visibility, with GLP-1 supplies likely from FY27, Entresto concerns seen as overdone, generics pricing stabilizing, planned capacity expansion, and superior long-term growth supporting premium valuations.

 15 Jul 2026 08:57 AM

Divi's Lab: Citi on Divi's Laboratories Maintains Buy with Target Price of ₹9,450 as GLP-1 and complex oral peptide opportunities (Tirzepatide, Orforglipron, Enlicitide, Icotrokinra) provide strong CY27–30 growth visibility, with GLP-1 supplies likely from FY27, Entresto concerns seen as overdone, generics pricing stabilizing, planned capacity expansion, and superior long-term growth supporting premium valuations.

Divi’s Labs: Jefferies maintains a Buy on Divi’s Labs with a Target Price of ₹7950, citing strong growth in Custom Synthesis and nutraceuticals, guidance for sustained double-digit INR growth, and ambitions to become a major peptide manufacturer, despite weak generics sales and regulatory uncertainty around key CS projects.

 25 May 2026 09:01 AM

Divi’s Labs: Jefferies maintains a Buy on Divi’s Labs with a Target Price of ₹7950, citing strong growth in Custom Synthesis and nutraceuticals, guidance for sustained double-digit INR growth, and ambitions to become a major peptide manufacturer, despite weak generics sales and regulatory uncertainty around key CS projects.

Divi’s Labs: Kotak Institutional Equities maintains a Sell on Divi’s Labs with a Target Price of ₹5850, citing a Q4 operating miss from softer CSM growth, high ongoing capex intensity, and expensive valuations despite strong client engagement and multiple peptide and CSM projects in the pipeline.

 25 May 2026 09:01 AM

Divi’s Labs: Kotak Institutional Equities maintains a Sell on Divi’s Labs with a Target Price of ₹5850, citing a Q4 operating miss from softer CSM growth, high ongoing capex intensity, and expensive valuations despite strong client engagement and multiple peptide and CSM projects in the pipeline.

Divi's Labs: Says Revenue From Capital Expenditure Is Hard To Forecast Due To Customer Schedules And Regulatory Approvals, With A Two-Year Estimate Being Optimistic. Management Notes That Margin Projections For FY27 Are Challenging, Yet Expected To Stay Stable Given The Current Conditions.

 25 May 2026 08:50 AM

Divi's Labs: Says Revenue From Capital Expenditure Is Hard To Forecast Due To Customer Schedules And Regulatory Approvals, With A Two-Year Estimate Being Optimistic. Management Notes That Margin Projections For FY27 Are Challenging, Yet Expected To Stay Stable Given The Current Conditions.

Divi's Labs: Forecasts Double-Digit Revenue Growth, Predicts Stable Margins Despite Uncertainty.

 25 May 2026 08:50 AM

Divi's Labs: Forecasts Double-Digit Revenue Growth, Predicts Stable Margins Despite Uncertainty.

DIVI'S LAB: Q4 CONS NET PROFIT 7.5B RUPEES VS 6.6B (YOY) || Q4 REVENUE 28.3B RUPEES VS 25.85B (YOY)

 23 May 2026 02:17 PM

DIVI'S LAB: Q4 CONS NET PROFIT 7.5B RUPEES VS 6.6B (YOY) || Q4 REVENUE 28.3B RUPEES VS 25.85B (YOY)

DIVI'S LAB.: Q4 EBITDA 10.7B RUPEES VS 8.86B (YOY) || Q4 EBITDA MARGIN 37.94% VS 34.3% (YOY)

 23 May 2026 02:18 PM

DIVI'S LAB.: Q4 EBITDA 10.7B RUPEES VS 8.86B (YOY) || Q4 EBITDA MARGIN 37.94% VS 34.3% (YOY)